DNTH
NASDAQ HealthcareDianthus Therapeutics, Inc. - Common Stock
Biotechnology
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
๐ Market Data
| Price | $95.35 |
|---|---|
| Volume | 1,174,897 |
| Market Cap | 5.21B |
| Beta | 0.090 |
| RSI (14-Day) | 55.1 |
| 200-Day MA | $62.86 |
| 50-Day MA | $88.64 |
| 52-Week High | $102.37 |
| 52-Week Low | $18.08 |
| Forward P/E | -20.50 |
| Price / Book | 4.33 |
๐ฏ Investment Strategy Scores
DNTH scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Institutional Whale (59/100) โ this strategy Large-cap, institutional-quality stocks.
Lowest fit among scored strategies: ๐ Moon Shot (10/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find DNTH in your text
Paste any article, transcript, or post โ the tool will extract DNTH and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.